This review describes the evidence associated with the direct and indirect economic costs of insomnia, as well as available and emerging therapeutic strategies.
We thank Brigitte Teissedre, PhD, Medicus International, for her editorial assistance in the preparation of the manuscript.
Author Affiliations: From Alertness Solutions (MRR, KBG), Cupertino, CA.
Funding Source: Editorial support was funded by sanofi-aventis. The authors were fully responsible for all content and editorial decisions and received no financial support or other compensation related to the development of the article.
Author Disclosures: The authors (MRR, KBG) report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article.
Authorship Information: Concept and design (MRR, KBG); drafting of the manuscript (MRR, KBG); and critical revision of the manuscript for important intellectual content (MRR, KBG).
Address correspondence to: Mark R. Rosekind, PhD, Alertness Solutions, 1601 S DeAnza Blvd, Ste 200, Cupertino, CA 95014. E-mail: email@example.com.
1. National Institutes of Health. NIH State-of-the-Science Conference: Manifestations and Management of Chronic Insomnia in Adults. June 13-15, 2005. http://consensus.nih.gov/previous.htm. Accessed June 9, 2010.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
3. Hohagen F, Käppler C, Schramm E, Riemann D, Weyerer S, Berger M. Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening: temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep. 1994;17(6):551-554.
4. Krystal AD. The effect of insomnia definitions, terminology, and classifications on clinical practice. J Am Geriatr Soc. 2005;53(7)(suppl):S258-S263.
5. National Heart, Lung, and Blood Institute and the NIH. Insomnia: key points. www.nhlbi.nih.gov/health/dci/Diseases/inso/inso_summary.html. Accessed May 2009.
6. Morin CM, LeBlanc M, Daley M, Gregoire JP, Mérette C. Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med. 2006;7(2):123-130.
7. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4(5):487-504.
8. Keklund G, Akerstedt T. Objective components of individual differences in subjective sleep quality. J Sleep Res. 1997;6(4):217-220.
9. Roberts RE, Roberts CR, Duong HT. Chronic insomnia and its negative consequences for health and functioning of adolescents: a 12-month prospective study. J Adolesc Health. 2008;42(3):294-302.
10. Roberts RE, Roberts CR, Duong HT. Sleepless in adolescence: prospective data on sleep deprivation, health and functioning. J Adolesc. 2009;2(5):1045-1057.
11. Partinen M, Leger D, Hirshkowitz M, Chokroverty S, Hedner J. Frequency of insomnia symptoms in PCPs’ patients: results of the Equinox International Survey. Paper presented at: European Sleep Research Society Meeting; September 9-13, 2008; Glasgow, Scotland.
12. Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey: I. Sleep. 1999;22(suppl 2):S347-S353.
13. Grandner MA, Kripke DF. Self-reported sleep complaints with long and short sleep: a nationally representative sample. Psychosom Med. 2004;66(2):239-241.
14. Rosenberg RP. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry. 2006;18(1):49-56.
15. National Sleep Foundation. Sleep in America Poll: data from 2002, 2003, 2004 and 2005 sleep polls. http://www.sleepfoundation.org/sites/default/files/2009%20Sleep%20in%20America%20SOF%20EMBARGOED.pdf. Accessed October 2009.
16. Leger D, Poursain B. An international survey of insomnia: underrecognition and under-treatment of a polysymptomatic condition. Curr Med Res Opin. 2005;21(11):1785-1792.
17. Owens JF, Matthews KA. Sleep disturbance in healthy middle-aged women. Maturitas. 1998;30(1):41-50.
18. Foley DJ, Monjan AA, Brown SL, Simonsick EM, Wallace RB, Blazer DG. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep. 1995;18(6):425-432.
19. Webb WB. Sleep in older persons: sleep structures of 50- to 60-year-old men and women. J Gerontol. 1982;37(5):581-586.
20. Linton S, Bryngelsson I. Insomnia and its relationship to work and health in a working-age population. J Occup Rehabil. 2000;10:169-183.
21. Akerstedt T. Shift work and disturbed sleep/wakefulness. Sleep Med Rev. 1998;2(2):117-128.
22. Watson NF, Goldberg J, Arguelles L, Buchwald D. Genetic and environmental influences on insomnia, daytime sleepiness, and obesity in twins. Sleep. 2006;29(5):645-649.
23. Bastien CH, Morin CM. Familial incidence of insomnia. J Sleep Res. 2000;9(1):49-54.
24. Parry BL, Fernando Martínez L, Maurer EL, López AM, Sorenson D, Meliska CJ. Sleep, rhythms and women’s mood, part II: menopause. Sleep Med Rev. 2006;10(3):197-208.
25. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol. 2000;96(3):351-358.
26. Pearson NJ, Johnson LL, Nahin RL. Insomnia, trouble sleeping, and complementary and alternative medicine: analysis of the 2002 National Health Interview Survey data. Arch Intern Med. 2006;166(16):1775-1782.
27. Fuller PM, Gooley JJ, Saper CB. Neurobiology of the sleep-wake cycle: sleep architecture, circadian regulation, and regulatory feedback. J Biol Rhythms. 2006;21(6):482-493.
28. Markov D, Goldman M. Normal sleep and circadian rhythms: neurobiologic mechanisms underlying sleep and wakefulness. Psychiatr Clin North Am. 2006;29(4):841-853, abstract vii.
29. Carskadon MA, Rechtschaffen A. Monitoring and staging human sleep. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 4th ed. Philadelphia, PA: Saunders; 2005.
30. Roth T. Measuring treatment efficacy in insomnia. J Clin Psychiatry. 2004;65(suppl 8):8-12.
31. Carskadon MA. Sleep and circadian rhythms in children and adolescents: relevance for athletic performance of young people. Clin Sports Med. 2005;24(2):319-328, x.
32. Jamison JR. Maintaining Health in Primary Care: Guidelines for Wellness in the 21st Century. Edinburgh, Scotland: Elsevier Health Sciences; 2001.
33. Gaillard JM. Is insomnia a disease of slow-wave sleep? Eur Neurol. 1976;14(6):473-484.
34. Gaillard JM. Chronic primary insomnia: possible physiopathological involvement of slow wave sleep deficiency. Sleep. 1978;1(2):133-147.
35. Merica H, Blois R, Gaillard JM. Spectral characteristics of sleep EEG in chronic insomnia. Eur J Neurosci. 1998;10(5):1826-1834.
36. Léger D, Scheuermaier K, Philip P, Paillard M, Guilleminault C. SF-36: evaluation of quality of life in severe and mild insomniacs compared with good sleepers. Psychosom Med. 2001;63(1):49-55.
37. Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep. 2007;30(8):959-968.
38. Winokur A, Gary KA, Rodner S, Rae-Red C, Fernando AT, Szuba MP. Depression, sleep physiology, and antidepressant drugs. Depress Anxiety. 2001;14(1):19-28.
39. Van Cauter E, Knutson KL. Sleep and the epidemic of obesity in children and adults. Eur J Endocrinol. 2008;159(suppl 1):S59-S66.
40. Smith S, Sullivan K, Hopkins W, Douglas J. Frequency of insomnia report in patients with obstructive sleep apnea hypopnea syndrome (OSAHS). Sleep Med. 2004;5(5):449-456.
41. Brower KJ. Insomnia, alcoholism and relapse. Sleep Med Rev. 2003;7(6):523-539.
42. Roth T. Comorbid insomnia: current directions and future challenges. Am J Manag Care. 2009;15(suppl):S6-S13.
43. Taylor DJ, Mallory LJ, Lichstein KL, Durrence HH, Riedel BW, Bush AJ. Comorbidity of chronic insomnia with medical problems [published correction appears in Sleep. 2007;30(7):table of contents]. Sleep. 2007;30(2):213-218.
44. Leigh TJ, Hindmarch I, Bird HA, Wright V. Comparison of sleep in osteoarthritic patients and age and sex matched healthy controls. Ann Rheum Dis. 1988;47(1):40-42.
45. Ancoli-Israel S. The impact and prevalence of chronic insomnia and other sleep disturbances associated with chronic illness. Am J Manag Care. 2006;12(8)(suppl):S221-S229.
46. Katz DA, McHorney CA. Clinical correlates of insomnia in patients with chronic illness. Arch Intern Med. 1998;158(10):1099-1107.
47. George CF, Bayliff CD. Management of insomnia in patients with chronic obstructive pulmonary disease. Drugs. 2003;63(4):379-387.
48. Skomro RP, Ludwig S, Salamon E, Kryger MH. Sleep complaints and restless legs syndrome in adult type 2 diabetics. Sleep Med. 2001;2(5):417-422.
49. Gottlieb DJ, Punjabi NM, Newman AB, et al. Association of sleep time with diabetes mellitus and impaired glucose tolerance. Arch Intern Med. 2005;165(8):863-867.
50. Riemann D, Berger M, Voderholzer U. Sleep and depression: results from psychobiological studies: an overview. Biol Psychol. 2001;57(1-3):67-103.
51. Roth T, Jaeger S, Jin R, Kalsekar A, Stang PE, Kessler RC. Sleep problems, comorbid mental disorders, and role functioning in the National Comorbidity Survey Replication. Biol Psychiatry. 2006;60(12):1364-1371.
52. Olson LG, Cole MF, Ambrogetti A. Correlations among Epworth Sleepiness Scale scores, multiple sleep latency tests and psychological symptoms. J Sleep Res. 1998;7(4):248-253.
53. Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry. 1996;39(6):411-418.
54. Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006;59(11):1052-1060.
55. Fava M, Asnis GM, Shrivastava R, et al. Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. J Clin Psychopharmacol. 2009;29(3):222-230.
56. Chilcott LA, Shapiro CM. The socioeconomic impact of insomnia: an overview. Pharmacoeconomics. 1996;10(suppl 1):1-14.
57. Nakata A, Ikeda T, Takahashi M, et al. Sleep-related risk of occupational injuries in Japanese small and medium-scale enterprises. Ind Health. 2005;43(1):89-97.
58. Akerstedt T, Fredlund P, Gillberg M, Jansson B. A prospective study of fatal occupational accidents: relationship to sleeping difficulties and occupational factors. J Sleep Res. 2002;11(1):69-71.
59. Pandi-Perumal SR, Verster JC, Kayumov L, et al. Sleep disorders, sleepiness and traffic safety: a public health menace. Braz J Med Biol Res. 2006;39(7):863-871.
60. Walsh JK. Clinical and socioeconomic correlates of insomnia. J Clin Psychiatry. 2004;65(suppl 8):13-19.
61. Ozminkowski RJ, Wang S, Walsh JK. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep. 2007;30(3):263-273.
62. Hatoum HT, Kong SX, Kania CM, Wong JM, Mendelson WB. Insomnia, health-related quality of life and healthcare resource consumption: a study of managed-care organisation enrollees. Pharmacoeconomics. 1998;14(6):629-637.
63. National Commission on Sleep Disorders Research. Wake Up America: A National Sleep Alert: Executive Summary and Executive Report. Bethesda, MD: National Heart, Lung, and Blood Institute; 1993:1.
64. Walsh JK, Engelhardt CL. The direct economic costs of insomnia in the United States for 1995. Sleep. 1999;22(suppl 2):S386-S393.
65. Fullerton DS. The economic impact of insomnia in managed care: a clearer picture emerges. Am J Manag Care. 2006;12(8)(suppl):S246-S252.
66. Stoller MK. Economic effects of insomnia. Clin Ther. 1994;16(5):873-897, 854.
67. Martin SA, Aikens JE, Chervin RD. Toward cost-effectiveness analysis in the diagnosis and treatment of insomnia. Sleep Med Rev. 2004;8(1):63-72.
68. Léger D, Guilleminault C, Bader G, Lévy E, Paillard M. Medical and socio-professional impact of insomnia. Sleep. 2002;25(6):625-629.
69. Kuppermann M, Lubeck DP, Mazonson PD, et al. Sleep problems and their correlates in a working population. J Gen Intern Med. 1995;10(1):25-32.
70. Kleinman NL, Brook RA, Doan JF, Melkonian AK, Baran RW. Health benefit costs and absenteeism due to insomnia from the employer’s perspective: a retrospective, case-control, database study. J Clin Psychiatry. 2009;70(8):1098-1104.
71. Rosekind MR, Gregory KB, Mallis MM, Brandt SL, Seal B, Lerner D. The cost of poor sleep: workplace productivity loss and associated costs. J Occup Environ Med. 2010;52(1):91-98.
72. Daley M, Morin CM, LeBlanc M, Grégoire JP, Savard J. The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. Sleep. 2009;32(1):55-64.
73. Jhaveri M, Seal B, Pollack M, Wertz D. Will insomnia treatments produce overall cost savings to commercial managed-care plans? a predictive analysis in the United States. Curr Med Res Opin. 2007;23(6):1431-1443.
74. Snedecor SJ, Botteman MF, Bojke C, Schaefer K, Barry N, Pickard AS. Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia. Sleep. 2009;32(6):817-824.
75. Morin AK. Strategies for treating chronic insomnia. Am J Manag Care. 2006;12(8)(suppl):S230-S245.
76. Lieberman JA. Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care. Prim Care Companion J Clin Psychiatry. 2007;9(1):25-31.
77. Ramakrishnan K, Scheid DC. Treatment options for insomnia. Am Fam Physician. 2007;76(4):517-526.
78. Taibi DM, Landis CA, Petry H, Vitiello MV. A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev. 2007;11(3):209-230.
79. Ebert B, Wafford KA, Deacon S. Treating insomnia: current and investigational pharmacological approaches. Pharmacol Ther. 2006;112(3):612-629.
80. Becker PM. Insomnia: prevalence, impact, pathogenesis, differential diagnosis, and evaluation. Psychiatr Clin North Am. 2006;29(4):855-870, abstract vii.
81. Owen RT. Ramelteon: profile of a new sleep-promoting medication. Drugs Today (Barc). 2006;42(4):255-263.
82. Roth T, Soubrane C, Titeux L, Walsh JK; Zoladult Study Group. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med. 2006;7(5):397-406.
83. Wagner J, Wagner ML. Non-benzodiazepines for the treatment of insomnia. Sleep Med Rev. 2000;4(6):551-581.
84. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Metaanalysis of benzodiazepine use in the treatment of insomnia. CMAJ. 2000;162(2):225-233.
85. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry. 2004;65(suppl 5):7-12.
86. Canaday BR. Amnesia possibly associated with zolpidem administration. Pharmacotherapy. 1996;16(4):687-689.
87. Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet. 2004;43(4):227-238.
88. Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. Jet lag: therapeutic use of melatonin and possible application of melatonin analogs. Travel Med Infect Dis. 2008;6(1-2):17-28.
89. Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med. 2006;7(1):17-24.
90. Benca RM. Diagnosis and treatment of chronic insomnia: a review. Psychiatr Serv. 2005;56(3):332-343.
91. Winokur A, DeMartinis NA III, McNally DP, Gary EM, Cormier JL, Gary KA. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry. 2003;64(10):1224-1229.
92. Montgomery SA. Safety of mirtazapine: a review [published correction appears in Int Clin Psychopharmacol. 1996;11(2):153]. Int Clin Psychopharmacol. 1995;10(suppl 4):37-45.
93. Bon OL. Low-dose trazodone effective in insomnia [letter]. Pharmacopsychiatry. 2005;38(5):226.
94. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66(4):469-476.
95. Walsh JK, Erman M, Erwin CW. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol. 1998;13:191-198.
96. White DP. Tragedy and insomnia. N Engl J Med. 2001;345(25):1846- 1848.
97. Reite M, Weissberg M, Ruddy J. Clinical Manual for Evaluation and Treatment of Sleep Disorders. Washington, DC: American Psychiatric Publishing; 2008.
98. Passarella S, Duong MT. Diagnosis and treatment of insomnia. Am J Health Syst Pharm. 2008;65(10):927-934.
99. Botteman MF, Ozminkowski RJ, Wang S, Pashos CL, Schaefer K, Foley DJ. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model [published correction appears in CNS Drugs. 2006;21(5):405]. CNS Drugs. 2007;21(4):319-334.
100. Botteman M. Health economics of insomnia therapy: implications for policy. Sleep Med. 2009;10(suppl 1):S22-S25.
101. Teegarden BR, Al Shamma H, Xiong Y. 5-HT(2A) inverse-agonists for the treatment of insomnia. Curr Top Med Chem. 2008;8(11):969-976.
102. Dukat M, Young R, Darmani NN, Ahmed B, Glennon RA. The 5-HT3 agent N-(3-chlorophenyl)guanidine (MD-354) serves as a discriminative stimulus in rats and displays partial agonist character in a shrew emesis assay. Psychopharmacology (Berl). 2000;150(2):200-207.
103. Sharpley AL, Williamson DJ, Attenburrow ME, Pearson G, Sargent P, Cowen PJ. The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology (Berl). 1996;126(1):50-54.
104. Viola AU, Brandenberger G, Toussaint M, Bouhours P, Paul Macher J, Luthringer R. Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers. Clin Neurophysiol. 2002;113(3):429-434.
105. Harrison NL. Mechanisms of sleep induction by GABAA receptor agonists. J Clin Psychiatry. 2007;68(suppl 5):6-12.
106. Szabadi E. Drugs for sleep disorders: mechanisms and therapeutic prospects. Br J Clin Pharmacol. 2006;61(6):761-766.
107. Nishino S. The hypocretin/orexin receptor: therapeutic prospective in sleep disorders. Expert Opin Investig Drugs. 2007;16(11):1785-1797.
108. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617-627.
109. Katzelnick DJ, Kobak KA, DeLeire T, et al. Impact of generalized social anxiety disorder in managed care. Am J Psychiatry. 2001;158(12):1999-2007.
110. Greenberg PE, Sisitsky T, Kessler RC, et al. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry. 1999;60(7):427-435.
111. DuPont RL, Rice DP, Miller LS, Shiraki SS, Rowland CR, Harwood HJ. Economic costs of anxiety disorders. Anxiety. 1996;2(4):167-172.
112. Johnson EO, Roth T, Breslau N. The association of insomnia with anxiety disorders and depression: exploration of the direction of risk. J Psychiatr Res. 2006;40(8):700-708.
113. Taylor DJ, Lichstein KL, Durrence HH, Reidel BW, Bush AJ. Epidemiology of insomnia, depression, and anxiety. Sleep. 2005;28(11):1457-1464.
114. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention? JAMA. 1989;262(11):1479-1484.
115. Henk HJ, Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW. Medical costs attributed to depression among patients with a history of high medical expenses in a health maintenance organization. Arch Gen Psychiatry. 1996;53(10):899-904.
116. Simon GE, VonKorff M, Barlow W. Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry. 1995;52(10):850-856.
117. Stensland MD, Jacobson JG, Nyhuis A. Service utilization and associated direct costs for bipolar disorder in 2004: an analysis in managed care. J Affect Disord. 2007;101(1-3):187-193.
118. Bryant-Comstock L, Stender M, Devercelli G. Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disord. 2002;4(6):398-405.
119. Harvey AG. Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony, and regulation. Am J Psychiatry. 2008;165(7):820-829.
120. Rice DP. Economic costs of substance abuse, 1995. Proc Assoc Am Physicians. 1999;111(2):119-125.
121. Crum RM, Storr CL, Chan YF, Ford DE. Sleep disturbance and risk for alcohol-related problems. Am J Psychiatry. 2004;161(7):1197-1203.
122. Centers for Disease Control and Prevention. 2007 National diabetes fact sheet. http://www.cdc.gov/diabetes/pubs/estimates07.htm#10. September 2009.
123. Hoerger TJ, Ahmann AJ. The impact of diabetes and associated cardiometabolic risk factors on members: strategies for optimizing outcomes. J Manag Care Pharm. 2008;14(1)(suppl C):S2-S14.
124. Zhou H, Isaman DJ, Messinger S, et al. A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care. 2005;28(12):2856-2863.
125. Brandle M, Zhou H, Smith BR, et al. The direct medical cost of type 2 diabetes. Diabetes Care. 2003;26(8):2300-2304.
126. Amin SP, Mullins CD, Duncan BS, Blandford L. Direct health care costs for treatment of diabetes mellitus and hypertension in an IPA-group-model HMO. Am J Health Syst Pharm. 1999;56(15):1515-1520.
127. Laliberté F, Bookhart BK, Vekeman F, et al. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. J Manag Care Pharm. 2009;15(4):312-322.
128. Centers for Disease Control and Prevention. Obesity Among Adults in the United States: No Statistically Significant Change Since 2003-2004. Hyattsville, MD: National Center for Health Statistics; 2007.
129. Stone KL, Blackwell T, Ancoli-Israel S. Objective measures of sleep duration and obesity in older men and women [abstract]. Sleep. 2007;30:A106-A107.
130. Patel SR, Blackwell T, Redline S, et al; Osteoporotic Fractures in Men Research Group, Study of Osteoporotic Fractures Research Group. The association between sleep duration and obesity in older adults. Int J Obes (Lond). 2008;32(12):1825-1834.
131. Centers for Disease Control and Prevention. FastStats: Asthma. http://www.cdc.gov/nchs/fastats/asthma.htm. Accessed August 3, 2010.
132. Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno A. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep. 2009;32(4):491-497.
133. American Lung Association. Chronic obstructive pulmonary disease (COPD) fact sheet (chronic bronchitis and emphysema). http://www.ingen-tech.com/PDFbin/COPDAmericanLun.pdf. Accessed June 10, 2010.
134. Menzin J, Boulanger L, Marton J, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population. Respir Med. 2008;102(9):1248-1256.
135. Blanchette CM, Gutierrez B, Ory C, Chang E, Akazawa M. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population. J Manag Care Pharm. 2008;14(2):176-185.